Select Medical Holdings Corporation (SEM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive sentiment with strong financial guidance, strategic partnerships, and a focus on growth in the inpatient rehab segment. Despite some challenges in the outpatient segment, management is optimistic about improvements, supported by a Medicare rate increase. The EPS guidance is raised, and the company is committed to enhancing shareholder value through dividends. The market strategy and capital allocation suggest a focus on sustainable growth, which is likely to lead to a positive stock price movement.
Key Financial Performance
Total Revenue (Q4 2025) Grew more than 6% year-over-year. Reasons for growth were not explicitly mentioned.
Adjusted EBITDA (Q4 2025) Declined 10% to $104.7 million from $116 million in the prior year. The decline was attributed to an increase in health insurance expenses, driven by elevated health-related costs, including higher cost claimants, increased utilization of medical and pharmacy benefits, and cost escalation.
Earnings per Common Share (Q4 2025) $0.16 versus a diluted loss per common share of $0.19 in the prior year. Reasons for the change were not explicitly mentioned.
Adjusted Earnings per Common Share (Q4 2025) $0.16 compared to $0.18 last year. The prior year figure excluded costs associated with the separation of Concentra, including accelerated stock-based compensation expense and a loss on early retirement of debt.
Full Year Revenue (2025) Grew more than 5%. Reasons for growth were not explicitly mentioned.
Adjusted EBITDA (Full Year 2025) $493.2 million with a 9% margin, compared to $510.4 million and a 9.8% margin in 2024. Reasons for the decline were not explicitly mentioned.
Earnings per Common Share (Full Year 2025) $1.16, up from $0.51 last year. Reasons for the increase were not explicitly mentioned.
Adjusted Earnings per Common Share (Full Year 2025) $1.16 compared to $0.94 in the prior year. Reasons for the increase were not explicitly mentioned.
Inpatient Rehab Hospital Division Revenue (Q4 2025) Increased over 15% year-over-year to $339.2 million. Reasons for growth were not explicitly mentioned.
Inpatient Rehab Hospital Division Adjusted EBITDA (Q4 2025) Rose 11% to $69.2 million. Reasons for growth were not explicitly mentioned.
Revenue per Patient Day (Inpatient Rehab Hospital Division, Q4 2025) Increased over 6%. Reasons for growth were not explicitly mentioned.
Average Daily Census (Inpatient Rehab Hospital Division, Q4 2025) Grew nearly 10%. Reasons for growth were not explicitly mentioned.
Occupancy (Inpatient Rehab Hospital Division, Q4 2025) Improved to 82% from 81%, with same-store occupancy rising to 86% from 85%. Reasons for improvement were not explicitly mentioned.
Adjusted EBITDA Margin (Inpatient Rehab Hospital Division, Q4 2025) 20.4% compared to 21.2% in the prior year. Reasons for the decline were not explicitly mentioned.
Critical Illness Recovery Hospital Division Revenue (Q4 2025) Increased nearly 5% to $629.7 million. Reasons for growth were not explicitly mentioned.
Critical Illness Recovery Hospital Division Adjusted EBITDA (Q4 2025) Grew 5% to $66.4 million from $63.1 million in the prior year. Reasons for growth were not explicitly mentioned.
Adjusted EBITDA Margin (Critical Illness Recovery Hospital Division, Q4 2025) Consistent with the prior year at 10.5%. Reasons for consistency were not explicitly mentioned.
Occupancy Rate (Critical Illness Recovery Hospital Division, Q4 2025) Remained steady at 67%, with admissions rising by 3%. Reasons for stability were not explicitly mentioned.
Outpatient Rehab Division Revenue (Q4 2025) Increased to $324.6 million from $319.6 million in the prior year. This was driven by nearly 5% growth in patient visits.
Net Revenue per Visit (Outpatient Rehab Division, Q4 2025) Declined to $98 from $102 compared to the same quarter last year. This decline was reflective of a reduction in Medicare reimbursement, an unfavorable shift in payer mix, and an increase in variable discounts.
Outpatient Rehab Division Adjusted EBITDA (Q4 2025) $11.2 million compared to $26.6 million last year, with margin declining to 3.4%. This decrease is primarily due to lower net revenue per visit and higher health insurance expense.
Debt Outstanding (End of Q4 2025) $1.8 billion. Reasons for the debt level were not explicitly mentioned.
Cash on Balance Sheet (End of Q4 2025) $26.5 million. Reasons for the cash level were not explicitly mentioned.
Interest Expense (Q4 2025) $28.9 million compared to $28.6 million in the same quarter last year. Reasons for the slight increase were not explicitly mentioned.
Cash Flow from Operating Activities (Q4 2025) $64.3 million. Reasons for the cash flow level were not explicitly mentioned.
Days Sales Outstanding (DSO, End of Q4 2025) 57 days at December 31, 2025, compared to 58 days at December 31, 2024, and 56 days at September 30, 2025. Reasons for the slight improvement were not explicitly mentioned.
Investing Activities (Q4 2025) Used $66.9 million, which includes $59.1 million for purchases of property and equipment and $9.1 million in acquisition and investment activity.
Financing Activities (Q4 2025) Used $31 million, including $50 million in net repayments on revolving line of credit, $38.1 million in net distributions to noncontrolling interest, $7.8 million in dividends, and $2.6 million in term loan repayments. Also received $51.3 million of net proceeds from other debt issuances.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Expansion of inpatient rehabilitation business: Added 150 beds in Q4 2025 through hospital openings and acquisitions, including partnerships with Cleveland Clinic, Riverside Health, and Vibra Healthcare. For the full year 2025, added 212 rehab beds. Plans to add 399 beds across 2026 and 2027, including new hospitals and expansions in Texas, Missouri, Arizona, New Jersey, and Florida.
Critical illness recovery hospital division: Added 10 beds in Savannah, Georgia, through acquisition. Plans for further expansions in 2026 and 2027.
Revenue growth: Total revenue grew more than 6% year-over-year in Q4 2025. Full-year revenue grew more than 5%.
Adjusted EBITDA: Declined 10% year-over-year in Q4 2025 to $104.7 million, primarily due to increased health insurance expenses.
Segment performance: Inpatient Rehab Hospital division revenue increased over 15% year-over-year, with adjusted EBITDA up 11%. Critical illness recovery hospital division revenue grew nearly 5%, with adjusted EBITDA up 5%. Outpatient rehab division revenue increased slightly, but adjusted EBITDA declined significantly due to lower net revenue per visit and higher health insurance expenses.
Take-private proposal: Received a nonbinding indication of interest to acquire all outstanding shares of Select Medical. A special committee is reviewing the proposal.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Adjusted EBITDA Decline: Adjusted EBITDA declined by 10% year-over-year in Q4 2025, primarily due to increased health insurance expenses driven by higher-cost claimants, increased utilization of medical and pharmacy benefits, and cost escalation. This decline impacts profitability and operational efficiency.
Outpatient Rehab Division Performance: Net revenue per visit in the outpatient rehab division declined from $102 to $98 due to a reduction in Medicare reimbursement, an unfavorable shift in payer mix, and increased variable discounts. Adjusted EBITDA for this division dropped significantly from $26.6 million to $11.2 million, with margins declining to 3.4%, indicating financial strain in this segment.
Debt Levels and Interest Expense: The company has $1.8 billion in debt, including $1.04 billion in term loans and $550 million in senior notes. Interest expense for the quarter was $28.9 million, slightly up from the prior year. High debt levels and associated costs could constrain financial flexibility.
Health Insurance Costs: Elevated health insurance expenses due to higher-cost claimants and increased utilization of benefits are negatively impacting financial performance, contributing to the decline in adjusted EBITDA.
Medicare Reimbursement and Payer Mix: A reduction in Medicare reimbursement and an unfavorable shift in payer mix are pressuring revenue in the outpatient rehab division, leading to lower net revenue per visit and reduced profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue is expected to be in the range of $5.6 billion to $5.8 billion for 2026.
Adjusted EBITDA: Adjusted EBITDA is projected to be in the range of $520 million to $540 million for 2026.
Earnings Per Share (EPS): Fully diluted earnings per common share is expected to fall in the range of $1.22 to $1.32 for 2026.
Capital Expenditures: Capital expenditures are expected to be in the range of $200 million to $220 million for 2026.
Inpatient Rehabilitation Expansion: The company plans to add 399 beds across 2026 and 2027, including new hospitals and expansions in various locations such as Texas, Missouri, Arizona, New Jersey, and Florida.
Upcoming Projects: Projects include a 60-bed hospital in Southern New Jersey (Q4 2026), two acute rehab units in Florida, and two neuro transitional units scheduled for Q2 and Q3 2026. A 76-bed rehab hospital in Jersey City and a 20-bed expansion in Arizona are planned for Q1 2027.
Long-term Growth Opportunities: Additional development opportunities are progressing through various stages, positioning the company for sustained growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Dividend: The Board of Directors approved a cash dividend of $0.0625 per share payable on March 12, 2026, to stockholders of record as of March 2, 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the impact of higher health costs on the outpatient rehab business?
A:The health insurance expense for the outpatient division was approximately $5 million for the quarter, and the variable discount impact was approximately $6 million, totaling around $11 million. The remainder of the delta was related to a shift in payer mix and softness in some markets.
Q:What are the expectations for guidance going forward, particularly for outpatient and critical illness segments?
A:Management is cautiously optimistic about outpatient improvement, believing the $11 million impact was a one-time issue. For critical illness, the fourth quarter was in line or slightly better than expected, and they are cautiously optimistic for next year, though the division is subject to variability.
Q:Can you expand on the special committee and potential strategic alternatives?
A:Management was unable to comment further on the process beyond what was mentioned at the beginning of the call.
Q:Was there any impact from weather in the first quarter?
A:There was no material impact on inpatient divisions for critical illness and inpatient rehab. However, there was some impact on outpatient in certain areas and states due to weather at the beginning of 2026.
Q:Why did health insurance only impact the outpatient division, and what is the $6 million variable discount?
A:Health insurance impacted the entire company but was more noticeable in outpatient due to its size and softness in certain areas. The $6 million variable discount relates to older receivables written off after exhausting collection efforts, primarily over a 2-year period.
Q:What caused the softness in some outpatient markets?
A:The softness was due to rate issues in some markets and staffing challenges, particularly in recruiting therapists. Management is focusing on addressing these issues in 2026.
Q:Can you provide detail on EBITDA guidance by segment?
A:Management does not provide segment-level guidance but noted that critical illness is expected to remain flat, inpatient rehab is expected to grow, and outpatient is expected to improve year-over-year despite tapering expectations due to Q3 and Q4 performance.
Q:Are the payer mix issues in outpatient the same as in the third quarter?
A:In the fourth quarter, there was an uptick in managed Medicare population, causing headwinds. Workers' comp was slightly down year-over-year. The deterioration in payer mix impacted net revenue per visit by about $1, while variable discounts impacted it by about $2.
Q:How will the Medicare rate increase in 2026 affect margins in outpatient?
A:Margins in the outpatient division are expected to improve year-over-year due to a 2% Medicare rate increase, the first in many years.
Q:What contributed to the $30 million EBITDA shortfall in the fourth quarter?
A:The shortfall was primarily due to $15 million in health insurance costs, timing issues in inpatient rehab development activities, and softness in the outpatient division.
Q:What caused the margin decline in the inpatient rehab segment?
A:The margin decline was due to start-up losses, which are timing issues and not related to the long-term viability of the segment. Same-store margins remained above 23%.
Q:Are there any concerns about the high-cost outlier threshold in the LTAC business?
A:The high-cost outlier threshold increased by $1,888, which is relatively flat compared to the prior year. Management does not expect major headwinds from this in 2026.
Q:What is the impact of the CMS team demo on the business?
A:The CMS team demo will have a minor impact, primarily on spinal fusion surgeries in a small proportion of rehab hospitals partnered with other systems.
Q:What are the plans for share repurchases and capital deployment in 2026?
A:Share repurchases are on hold due to the ongoing review process. Capital deployment will focus on growing inpatient rehab hospitals, new rehab units, and neuro transitional centers.
Q:Are there any applications of AI being explored?
A:Management is evaluating AI for back-end processes in billing, outpatient collections, virtual sitters, and telemetry monitoring.
Q:What is the status of labor in the critical illness segment?
A:Labor costs have stabilized, with agency rates settling post-2022 challenges. The labor margin is running just above 56%, and there are no significant union threats on the horizon.
Q:What are the expected start-up expenses for the inpatient rehab segment in 2026?
A:Start-up expenses are expected to be relatively consistent year-over-year, around $15 million, slightly south of that figure.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to questions about the special committee and potential strategic alternatives, stating they could not comment beyond what was mentioned earlier in the call.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arizona venture
Atlanta Care
Care Southern
Chairman nonbinding
City Banner
Concentra stock
CoxHealth Ozark
Directors process
Florida neuro
Georgia illness
Health Temple
Health Virginia
Healthcare Southern
Kentucky
Officer
President Chief
acquisition bed
bed expansion
bed hospital
bed rehabilitation
committee
health insurance
hospital division
illness recovery
insurance expense
neuro unit
project
proposal
recovery hospital
rehab unit
rehabilitation hospital
unit bed
update
SEM Transcript
EcoSynthetix Inc. (ECO:CA) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary and Q&A section reveal a positive outlook. Financial performance is strong with increased EPS guidance and reaffirmed revenue expectations. Product development shows growth in new rehabilitation facilities and active pipeline opportunities. The market strategy is solid with strategic investments and partnerships. Expenses are manageable with positive EBITDA. Shareholder return plans include dividends and potential share repurchases. Despite some vague responses in the Q&A, the overall sentiment is optimistic, supported by strategic growth and financial strength. Given the company's market cap, a positive stock movement of 2% to 8% is likely.
Select Medical Holdings Corporation (SEM) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call reflects a positive sentiment with strong financial guidance, strategic partnerships, and a focus on growth in the inpatient rehab segment. Despite some challenges in the outpatient segment, management is optimistic about improvements, supported by a Medicare rate increase. The EPS guidance is raised, and the company is committed to enhancing shareholder value through dividends. The market strategy and capital allocation suggest a focus on sustainable growth, which is likely to lead to a positive stock price movement.
Select Medical Holdings Corporation (SEM) Q3 2025 Earnings Call Transcript
Unknown10-31
Despite strong financial metrics and expansion plans, the lack of raised guidance due to outpatient segment softness and unchanged EBITDA guidance offset positive impacts. The Q&A revealed pressures from Medicare rates and payer mix shifts, which may concern investors. The market cap suggests moderate stock price movement. Thus, a neutral rating is appropriate.
Select Medical Holdings Corporation (SEM) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong revenue growth in some divisions, but challenges in critical illness recovery. The reaffirmed guidance and strategic focus on joint ventures are positive. However, regulatory issues and unclear management responses about critical illness impact cast doubts. The stock repurchase is a positive sign, but the debt level and margin declines in some areas are concerning. Given the market cap and mixed signals, a neutral stock price reaction is expected.
SEM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
